BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amber KT, Valdebran M, Kridin K, Grando SA. The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Front Med (Lausanne) 2018;5:201. [PMID: 30042946 DOI: 10.3389/fmed.2018.00201] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Heydari P, Kharaziha M, Varshosaz J, Javanmard SH. Current knowledge of immunomodulation strategies for chronic skin wound repair. J Biomed Mater Res B Appl Biomater 2021. [PMID: 34318595 DOI: 10.1002/jbm.b.34921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hammers CM, Stanley JR. Recent Advances in Understanding Pemphigus and Bullous Pemphigoid. Journal of Investigative Dermatology 2020;140:733-41. [DOI: 10.1016/j.jid.2019.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment Update of Autoimmune Blistering Diseases. Dermatologic Clinics 2019;37:215-28. [DOI: 10.1016/j.det.2018.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
4 Wang SH, Zuo YG. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Front Immunol 2021;12:800609. [PMID: 34887875 DOI: 10.3389/fimmu.2021.800609] [Reference Citation Analysis]
5 Liu Y, Wang Y, Chen X, Jin H, Li L. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med 2020;52:55-62. [PMID: 32163298 DOI: 10.1080/07853890.2020.1742367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmunity Reviews 2019;18:526-34. [DOI: 10.1016/j.autrev.2019.03.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
7 Sezin T, Ferreirós N, Jennrich M, Ochirbold K, Seutter M, Attah C, Mousavi S, Zillikens D, Geisslinger G, Sadik CD. 12/15-Lipoxygenase choreographs the resolution of IgG-mediated skin inflammation. Journal of Autoimmunity 2020;115:102528. [DOI: 10.1016/j.jaut.2020.102528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang SH, Zuo YG. Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases. Front Immunol 2021;12:698522. [PMID: 34249003 DOI: 10.3389/fimmu.2021.698522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Tabatabaei-Panah PS, Moravvej H, Alirajab M, Etaaty A, Geranmayeh M, Hosseine F, Khansari A, Mahdian M, Mirhashemi M, Parvizi S, Sakhaie F, Ludwig RJ, Akbarzadeh R. Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid. Immunol Invest 2020;:1-13. [PMID: 33047635 DOI: 10.1080/08820139.2020.1832113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang Y, Mao X, Liu Y, Yang Y, Jin H, Li L. IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker. Front Immunol 2022;13:824110. [DOI: 10.3389/fimmu.2022.824110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs 2018;78:1527-48. [PMID: 30238396 DOI: 10.1007/s40265-018-0976-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
12 Maglie R, Hertl M. Pharmacological advances in pemphigoid. Current Opinion in Pharmacology 2019;46:34-43. [DOI: 10.1016/j.coph.2018.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
13 Schauer F, Rafei-shamsabadi D, Mai S, Mai Y, Izumi K, Meiss F, Kiritsi D. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study. Front Immunol 2022;13:953546. [DOI: 10.3389/fimmu.2022.953546] [Reference Citation Analysis]
14 Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Front Immunol 2019;10:1506. [PMID: 31312206 DOI: 10.3389/fimmu.2019.01506] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
15 Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, Yokozeki H, Yosipovitch G. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol 2020;83:53-62. [PMID: 31351883 DOI: 10.1016/j.jaad.2019.07.060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
16 Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid. Journal of Allergy and Clinical Immunology 2020;145:1031-47. [DOI: 10.1016/j.jaci.2020.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
17 Jones VA, Patel PM, Gibson FT, Cordova A, Amber KT. The Role of Collagen XVII in Cancer: Squamous Cell Carcinoma and Beyond. Front Oncol 2020;10:352. [PMID: 32266137 DOI: 10.3389/fonc.2020.00352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Izumi K, Bieber K, Ludwig RJ. Current Clinical Trials in Pemphigus and Pemphigoid. Front Immunol 2019;10:978. [PMID: 31130959 DOI: 10.3389/fimmu.2019.00978] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
19 Lamberts A, Kotnik N, Diercks GFH, Meijer JM, Di Zenzo G, Pas HH, Jonkman MF, Gibbs BF, Raap U, Horváth B. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients. J Eur Acad Dermatol Venereol 2021;35:973-80. [PMID: 33058320 DOI: 10.1111/jdv.16996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Amber KT, Chernyavsky A, Agnoletti AF, Cozzani E, Grando SA. Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol 2018;27:1322-7. [PMID: 30218612 DOI: 10.1111/exd.13782] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Szilveszter KP, Németh T, Mócsai A. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. Front Immunol 2019;10:1862. [PMID: 31447854 DOI: 10.3389/fimmu.2019.01862] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
22 Ko KI, Merlet JJ, DerGarabedian BP, Zhen H, Suzuki-Horiuchi Y, Hedberg ML, Hu E, Nguyen AT, Prouty S, Alawi F, Walsh MC, Choi Y, Millar SE, Cliff A, Romero J, Garvin MR, Seykora JT, Jacobson D, Graves DT. NF-κB perturbation reveals unique immunomodulatory functions in Prx1+ fibroblasts that promote development of atopic dermatitis. Sci Transl Med 2022;14:eabj0324. [PMID: 35108061 DOI: 10.1126/scitranslmed.abj0324] [Reference Citation Analysis]
23 Cole C, Vinay K, Borradori L, Amber KT. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Front Immunol 2022;13:912876. [DOI: 10.3389/fimmu.2022.912876] [Reference Citation Analysis]
24 Khalid SN, Khan ZA, Ali MH, Almas T, Khedro T, Raj Nagarajan V. A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions. Ann Med Surg (Lond) 2021;70:102799. [PMID: 34540212 DOI: 10.1016/j.amsu.2021.102799] [Reference Citation Analysis]
25 Antiga E, Maglie R, Quintarelli L, Verdelli A, Bonciani D, Bonciolini V, Caproni M. Dermatitis Herpetiformis: Novel Perspectives. Front Immunol 2019;10:1290. [PMID: 31244841 DOI: 10.3389/fimmu.2019.01290] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
26 Alaibac M. Biological therapy of autoimmune blistering diseases. Expert Opin Biol Ther 2019;19:149-56. [PMID: 30558452 DOI: 10.1080/14712598.2019.1559291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Messingham KN, Crowe TP, Fairley JA. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid. Front Immunol 2019;10:2331. [PMID: 31636640 DOI: 10.3389/fimmu.2019.02331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
28 Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. J Transl Med 2021;19:520. [PMID: 34930319 DOI: 10.1186/s12967-021-03192-8] [Reference Citation Analysis]
29 Morais KL, Miyamoto D, Maruta CW, Aoki V. Diagnostic approach of eosinophilic spongiosis. An Bras Dermatol 2019;94:724-8. [PMID: 31789265 DOI: 10.1016/j.abd.2019.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Afarideh M, Borucki R, Werth VP. A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets. J Clin Med 2022;11:2856. [PMID: 35628982 DOI: 10.3390/jcm11102856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Papara C, Zillikens D, Sadik CD, Baican A. MicroRNAs in pemphigus and pemphigoid diseases. Autoimmun Rev 2021;20:102852. [PMID: 33971341 DOI: 10.1016/j.autrev.2021.102852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Valdebran M, Kowalski EH, Kneiber D, Li J, Kim J, Doan L, De Feraudy S, Amber KT. Epidermal expression of eotaxins and thymic stromal lymphopoietin in eosinophil rich dermatoses. Arch Dermatol Res 2019;311:705-10. [PMID: 31350578 DOI: 10.1007/s00403-019-01954-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Liu Y, Li L. Commentary: Proinflammatory role of blister fluid-derived exosomes in bullous pemphigoid. Front Immunol 2020;11:1506. [PMID: 32765519 DOI: 10.3389/fimmu.2020.01506] [Reference Citation Analysis]
34 Kridin K, Kowalski EH, Kneiber D, Laufer-Britva R, Amber KT. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. J Eur Acad Dermatol Venereol 2019;33:2239-52. [PMID: 31314932 DOI: 10.1111/jdv.15816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
35 Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules 2020;10:E1432. [PMID: 33050407 DOI: 10.3390/biom10101432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Stevens NE, Cowin AJ, Kopecki Z. Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin. Front Immunol 2019;10:1089. [PMID: 31156638 DOI: 10.3389/fimmu.2019.01089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Ständer S, Hammers CM, Vorobyev A, Schmidt E, Zillikens D, Ghorbanalipoor S, Bieber K, Ludwig RJ, Kridin K. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid. J Eur Acad Dermatol Venereol 2021;35:1702-11. [PMID: 33896060 DOI: 10.1111/jdv.17303] [Reference Citation Analysis]
38 Chen X, Zhao W, Jin H, Li L. Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review. Front Med (Lausanne) 2021;8:680871. [PMID: 34095183 DOI: 10.3389/fmed.2021.680871] [Reference Citation Analysis]
39 Zeidler C, Pereira MP, Huet F, Misery L, Steinbrink K, Ständer S. Pruritus in Autoimmune and Inflammatory Dermatoses. Front Immunol 2019;10:1303. [PMID: 31293565 DOI: 10.3389/fimmu.2019.01303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
40 Patel PM, Jones VA, Behnam CT, Zenzo GD, Amber KT. A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy. Antibodies (Basel) 2021;10:19. [PMID: 34067512 DOI: 10.3390/antib10020019] [Reference Citation Analysis]
41 Giusti D, Bini E, Terryn C, Didier K, Le Jan S, Gatouillat G, Durlach A, Nesmond S, Muller C, Bernard P, Antonicelli F, Pham BN. NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay. Front Immunol 2019;10:701. [PMID: 31019514 DOI: 10.3389/fimmu.2019.00701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
42 Gehring M, Wieczorek D, Kapp A, Wedi B. Potent Anti-Inflammatory Effects of Tetracyclines on Human Eosinophils. Front Allergy 2021;2:754501. [DOI: 10.3389/falgy.2021.754501] [Reference Citation Analysis]
43 Cugno M, Borghi A, Garcovich S, Marzano AV. Coagulation and Skin Autoimmunity. Front Immunol 2019;10:1407. [PMID: 31281319 DOI: 10.3389/fimmu.2019.01407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
44 Saxena Y, Routh S, Mukhopadhaya A. Immunoporosis: Role of Innate Immune Cells in Osteoporosis. Front Immunol 2021;12:687037. [PMID: 34421899 DOI: 10.3389/fimmu.2021.687037] [Reference Citation Analysis]
45 Jacobsen EA, Jackson DJ, Heffler E, Mathur SK, Bredenoord AJ, Pavord ID, Akuthota P, Roufosse F, Rothenberg ME. Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annu Rev Immunol 2021;39:719-57. [PMID: 33646859 DOI: 10.1146/annurev-immunol-093019-125918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
46 Qiu L, Zhang L, Qi R, Gao X, Chen H, Xiao T. miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid. Dis Markers 2020;2020:9505312. [PMID: 32399091 DOI: 10.1155/2020/9505312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Patel PM, Jones VA, Kridin K, Amber KT. The role of Dipeptidyl Peptidase-4 in cutaneous disease. Exp Dermatol 2021;30:304-18. [PMID: 33131073 DOI: 10.1111/exd.14228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]